[Human immunodeficiency virus type 2 infection].

K Mansinho

Home/Archive/PubMed

PubMed · 10892439

[Human immunodeficiency virus type 2 infection].

K Mansinho

View original source ↗Export metadata ↓

Abstract

The isolation of a second retrovirus, HIV-2, led to fears that a second AIDS pandemic, similar in scope and magnitude to that caused by HIV-1, might ensue. However, the peculiar biologic properties of HIV-2, namely the lower transmissibility of this virus through both sexual and vertical routes, contributed to a more regionalized distribution of the virus, which became endemic in West Africa. HIV-2 is genetically more closely related to SIV than to HIV-1. When it comes to clinical disease, the spectrum of opportunistic infections and tumors (except for Kaposi sarcoma) are similar to that observed with HIV-1. Controlled longitudinal studies suggest that the rate of progression to advanced HIV related disease and mortality are far lower for HIV-2 than for HIV-1. Understanding how, immunologically and virologically, HIV-2 behaves differently from HIV-1 may provide some insight into the mechanisms governing HIV-1 pathogenesis.

Explore related subjects

HIV Infections HIV-2 Humans English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

K Mansinho. 1999. [Human immunodeficiency virus type 2 infection].. https://pubmed.ncbi.nlm.nih.gov/10892439/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2025

HIV-phyloTSI: subtype-independent estimation of time since HIV-1 infection for cross-sectional measures of population incidence using deep sequence data.

BACKGROUND: Estimating the time since HIV infection (TSI) at population level is essential for tracking changes in the global HIV epidemic. Most methods for determining TSI give a binary classification of infections as recent or non-recent within a window of several months, and cannot assess the cumulative impact of an intervention. RESULTS: We developed a Random Forest Regression model, HIV-phyloTSI, which combines measures of within-host diversity and divergence to generate continuous TSI estimates directly from viral deep-sequencing data, with no need for additional variables. HIV-phyloTSI provides a continuous measure of TSI up to 9 years, with a mean absolute error of less than 12 months overall and less than 5 months for infections with a TSI of up to a year. It performs equally well for all major HIV subtypes based on data from African and European cohorts. CONCLUSIONS: We demonstrate how HIV-phyloTSI can be used for incidence estimates on a population level.

HIV Infections↗

PubMed2007

Appropriate evaluation of HIV prevention interventions: from experiment to full-scale implementation.

BACKGROUND: Preventing HIV infection is still an essential goal in tackling the HIV/AIDS pandemic. Remarkably little is known about how best to reduce HIV incidence because most trials focus on the reduction of risk behaviours and assume an effect on HIV incidence. OBJECTIVE: To discuss the evidence for the effectiveness of HIV prevention strategies, exploring the different types of evidence available: individual and community randomised controlled trials, and observational studies. RESULTS: Although providing a gold standard for evidence, trials have been limited in their scope and are difficult to interpret and generalize. There have been examples of national level successes in preventing HIV which have been detected in surveillance data and understood through behavioural and modelling studies. These have the advantage of being to scale and indicating effectiveness rather than efficacy. CONCLUSIONS: Although randomised trials are important because of their scientific rigor, it is also important that evidence from observational epidemiology is not overlooked. Only if good quality, consistent data are available can the history of the HIV epidemic be appropriately analysed.

HIV Infections↗

PubMed2007

Protein i: interference at protein level by intrabodies.

Immunoglobulin molecules have long been used in biomedical research as in vitro tools for identification, purification and functional manipulation of target proteins. The specificity and diversity of immunoglobulins can be exploited to target a wide range of intracellular proteins by expressing them in vivo. Such antibody molecules, which are expressed intracellularly and directed to defined sub-cellular compartments, are termed 'intrabodies'. They represent a new and versatile tool that has the potential to manipulate diverse biological processes. Gene knockout, antisense and small interfering RNA knockdown techniques, are employed to characterize the function of many gene products and to validate these gene products as potential drug targets for novel therapeutics, but they have their limitations. The experimental results to date suggest that intrabodies represent a powerful alternative to modulate protein function and analyze its effects. Moreover, they can also be utilized to target specific domains of a particular target protein. Even though their clinical application might take a long time, they can play an important role for target identification and validation in functional genomics and/or proteomics. Here we review the latest advances in the concept, construction and applications of Intrabodies.

HIV Infections↗